Targeting DIPG through therapeutic dietary intervention
Diffuse Intrinsic Pontine Gliomas(DIPG) are aggressive brain tumorsin children that currently have no effective treatments. Most DIPG cases (over 70%) involve a mutation in a gene called H3K27M, which changes how genes are regulated and affects the tumor’s behavior. Although scientists now better understand these gene changes, new treatments are still needed to improve outcomes for children with DIPG. Cancer cells often change their metabolism to grow faster. These changes affect how enzymes work and influence gene regulation. DIPG tumors with the H3K27M mutation show changes in how they process sugar (glycolysis), glutamine, and the TCA cycle. Blocking enzymes in these pathways affects gene activity, but it’s still unclear if these gene changes alter the tumor’s metabolism directly or indirectly. Our new research suggeststhat DIPG tumorsrely heavily on breaking down branched chain amino acids(BCAAs) for survival. We found that: (1) DIPG cells consume more BCAAsthan normal. (2) BCAT1, an enzyme that breaks down BCAAs, is highly active and found in the cell nucleus. (3) DIPG cells with the H3K27M mutation need BCAT1 to survive, unlike normal cells. (4) Blocking BCAT1 reduces certain histone modifications important for maintaining the tumor. Thus, we propose that DIPG tumors depend on histone changes driven by BCAA metabolism and suggest that limiting BCAAs through diet could slow tumor growth, offering a potential new treatment strategy.
Project Goals
Goal 1: Understand how BCAT1 helps DIPG tumors grow. Our team will block BCAT1 (a key enzyme) using genetic and drug-based methods to see how it affects DIPG growth. They will analyze how BCAAs (branched-chain amino acids) are broken down and used to modify histones (proteins that control gene activity), especially through a process called propionylation. Since BCAT1 in the nucleus may produce propionyl-CoA, which promotes tumor growth by activating key genes, this study will explore that connection.
Goal 2: Test if reducing BCAAsin the diet can slow DIPG growth. Scientists will feed special diets without BCAAsto mice with DIPG to see if this slows tumor growth and improves survival. They will use advanced tools to track changes in tumor cell identity and gene activity, predicting that restricting BCAAs will push DIPG cells to become less aggressive and delay progression.
Why This Matters: This research explores how DIPG tumors use nutrients, particularly BCAAs, to survive and grow. Since these tumors can’t make their own BCAAs, limiting BCAAs in the diet could provide a new, effective treatment. Importantly, similar diets are already used in treating metabolic disorders, making this approach easier to translate into clinical practice. This work introduces a new idea that BCAT1-driven BCAA metabolism controls histone modifications and that cutting off this nutrient source may be a novel way to slow or stop DIPG progression.
